Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First- Episode Schizophrenia Patients
| Autor: | Valentino Rački, Mirjana Graovac, Daniela Petrić, Ana Kaštelan, Nadija Gačo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences Adolescent medicine.medical_treatment Long-Acting injectable antipsychotic psychopharmacology child and adolescent Weight Gain First episode schizophrenia 03 medical and health sciences 0302 clinical medicine Paliperidone Palmitate medicine Retrospective analysis Brief Psychiatric Rating Scale Humans Pharmacology (medical) Long-Acting injectable antipsychotic Antipsychotic child and adolescent Retrospective Studies psychopharmacology business.industry BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences Risperidone medicine.disease 030227 psychiatry Hospitalization Hyperprolactinemia Psychiatry and Mental health Long acting Tolerability Schizophrenia Pediatrics Perinatology and Child Health Female business BIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti 030217 neurology & neurosurgery Antipsychotic Agents |
| Zdroj: | Journal of Child and Adolescent Psychopharmacology Volume 29 Issue 3 |
| ISSN: | 1044-5463 |
| Popis: | OBJECTIVE: The aim of this study was to explore the effectiveness and tolerability of long- acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone. METHODS: This study is a retrospective, noninterventional study to assess the effectiveness and tolerability of long-acting injectable antipsychotic paliperidone palmitate in first-episode adolescent patients during the first 12 months of treatment compared with the oral antipsychotic risperidone. The data include general sociodemographic characteristics, number of hospitalizations, side effects, and the following clinical scales: Positive and Negative Syndrome Scale (PANSS), Personal and Social Performance Scale (PSP), Clinical Global Impression Improvement and Severity (CGI-I and CGI-S), and Treatment Satisfaction Questionnaire for Medication (TSQM). RESULTS: During the 12- month study period significant improvement was registered in patients receiving both paliperidone palmitate and risperidone in the following scales: PANSS, PSP, CGI-I, and CGI-S. Patients receiving paliperidone palmitate had significantly greater improvement in PANSS, CGI- S, and PSP compared with the risperidone group. Patients receiving risperidone had significantly higher number of hospitalizations than the patients receiving paliperidone palmitate. The TSQM revealed that the patients who were receiving paliperidone palmitate achieved significantly higher scores on the convenience scale, global satisfaction, and on the overall result, whereas no difference was observed on the effectiveness scale. There were several side effects reported for paliperidone (5.5% hyperprolactinemia, 5.5% weight gain) and risperidone (5.5% hyperprolactinemia, 16.7% weight gain). CONCLUSIONS: In conclusion, paliperidone palmitate seems to be safe and effective in adolescent patients. Furthermore, it compared favorably with risperidone in the clinical response, side effects, and hospitalizations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|